Comparative Pharmacology
Head-to-head clinical analysis: LORATADINE REDIDOSE versus OPTIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORATADINE REDIDOSE versus OPTIMINE.
LORATADINE REDIDOSE vs OPTIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
OPTIMINE (azathioprine) is a purine analog that inhibits DNA and RNA synthesis by interfering with purine metabolism. It is metabolized to 6-mercaptopurine, which inhibits de novo purine synthesis and suppresses T-lymphocyte proliferation.
10 mg orally once daily
1 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Terminal elimination half-life of 12-15 hours in healthy adults, prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Renal: 65-75% as unchanged drug; biliary/fecal: 20-30% as metabolites; minor hepatic metabolism via CYP3A4.
Category A/B
Category C
Antihistamine
Antihistamine